Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure

NCT04352205 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

17

Enrollment

OTHER

Sponsor class

Stopped Slow accrual

Conditions

Plasma Cell Myeloma
Renal Failure

Interventions

DRUG: Bortezomib
BIOLOGICAL: Daratumumab
DRUG: Dexamethasone
DRUG: Lenalidomide
DRUG: Thalidomide

Sponsor

Emory University

Collaborators

[object Object]
[object Object]